cardinal health glp-1 receptor agonist weight management diabetes treatments Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 Receptor Agonists as Treatments

Understanding the characteristics and features of these devices can therefore aid both physicians and their patients in selecting the most appropriate agent

doi: 10.2147/DMSO.S439587

Call (520) 298-3300.

Ongoing research is ongoing to explore broader therapeutic applications

It works by mimicking the effect of the naturally occurring hormone GLP-1, which is crucial for triggering insulin release from the pancreas, enhancing the feeling of fullness (satiety), slowing down stomach emptying, and inhibiting glucagon secretion

Of the numerous prospective randomized clinical trials evaluating the influence of GLP-1 RA use on cardiovascular outcomes (Table 1), only the ELIXA study of lixisenatide [28] has thus far published its results